Switch theme
Sign up to access all valuation multiples
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
2014
123
LTM Revenue $51.2M
Last FY EBITDA -$291M
$256M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Amylyx Pharmaceuticals has a last 12-month revenue (LTM) of $51.2M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Amylyx Pharmaceuticals achieved revenue of $87.4M and an EBITDA of -$291M.
Amylyx Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Amylyx Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $51.2M | XXX | $87.4M | XXX | XXX | XXX |
| Gross Profit | -$21.8M | XXX | -$37.3M | XXX | XXX | XXX |
| Gross Margin | -43% | XXX | -43% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$291M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -333% | XXX | XXX | XXX |
| EBIT | -$250M | XXX | -$292M | XXX | XXX | XXX |
| EBIT Margin | -488% | XXX | -334% | XXX | XXX | XXX |
| Net Profit | -$239M | XXX | -$302M | XXX | XXX | XXX |
| Net Margin | -466% | XXX | -345% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Amylyx Pharmaceuticals's stock price is $5.
Amylyx Pharmaceuticals has current market cap of $459M, and EV of $256M.
See Amylyx Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $256M | $459M | XXX | XXX | XXX | XXX | $-3.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Amylyx Pharmaceuticals has market cap of $459M and EV of $256M.
Amylyx Pharmaceuticals's trades at 2.9x EV/Revenue multiple, and -0.9x EV/EBITDA.
Equity research analysts estimate Amylyx Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Amylyx Pharmaceuticals has a P/E ratio of -1.9x.
See valuation multiples for Amylyx Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $459M | XXX | $459M | XXX | XXX | XXX |
| EV (current) | $256M | XXX | $256M | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.9x | XXX | XXX | XXX |
| EV/EBIT | -1.0x | XXX | -0.9x | XXX | XXX | XXX |
| EV/Gross Profit | -11.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.9x | XXX | -1.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAmylyx Pharmaceuticals's last 12 month revenue growth is -100%
Amylyx Pharmaceuticals's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $2.1M for the same period.
Amylyx Pharmaceuticals's rule of 40 is -89% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Amylyx Pharmaceuticals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Amylyx Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | -96% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -333% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -89% | XXX | -433% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 161% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 291% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Amylyx Pharmaceuticals acquired XXX companies to date.
Last acquisition by Amylyx Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Amylyx Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Amylyx Pharmaceuticals founded? | Amylyx Pharmaceuticals was founded in 2014. |
| Where is Amylyx Pharmaceuticals headquartered? | Amylyx Pharmaceuticals is headquartered in United States of America. |
| How many employees does Amylyx Pharmaceuticals have? | As of today, Amylyx Pharmaceuticals has 123 employees. |
| Who is the CEO of Amylyx Pharmaceuticals? | Amylyx Pharmaceuticals's CEO is Mr. Joshua Cohen. |
| Is Amylyx Pharmaceuticals publicy listed? | Yes, Amylyx Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Amylyx Pharmaceuticals? | Amylyx Pharmaceuticals trades under AMLX ticker. |
| When did Amylyx Pharmaceuticals go public? | Amylyx Pharmaceuticals went public in 2022. |
| Who are competitors of Amylyx Pharmaceuticals? | Similar companies to Amylyx Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Amylyx Pharmaceuticals? | Amylyx Pharmaceuticals's current market cap is $459M |
| What is the current revenue of Amylyx Pharmaceuticals? | Amylyx Pharmaceuticals's last 12 months revenue is $51.2M. |
| What is the current revenue growth of Amylyx Pharmaceuticals? | Amylyx Pharmaceuticals revenue growth (NTM/LTM) is -100%. |
| What is the current EV/Revenue multiple of Amylyx Pharmaceuticals? | Current revenue multiple of Amylyx Pharmaceuticals is 5.0x. |
| Is Amylyx Pharmaceuticals profitable? | Yes, Amylyx Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
